Roche?s marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis
- European Medicines Agency (EMA) grants Accelerated Assessment for satralizumab application